Nifuroxazide-d4 |
カタログ番号GC48839
One-Click Copy Product Info
|
ニフロキサジドの定量化のための内部標準
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1188487-83-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Nifuroxazide-d4 is intended for use as an internal standard for the quantification of nifuroxazide by GC- or LC-MS. Nifuroxazide is a nitrofuran antibiotic.1 It is active against strains of the enteropathogenic bacteria C. jejuni, Salmonella, Y. enterocolitica, Shigella, and E. coli.1 It inhibits quorum sensing and virulence factor production in P. aeruginosa.2 Nifuroxazide inhibits STAT3 activity in a reporter assay (IC50 = ~3 µM) and decreases viability of U266 and INA-6 myeloma cells, which have constitutive STAT3 phosphorylation, with EC50 values of approximately 4.5 µM for both.3 It also decreases viability, migration, and invasion of, and induces apoptosis in, MCF-7, 4T1, and MDA-MB-231 breast cancer cells.4 Nifuroxazide (50 mg/kg per day) reduces tumor growth and prevents pulmonary metastasis in a 4T1 murine mammary carcinoma model. It also reduces diarrhea, weight loss, and colon inflammation in a rat model of acetic acid-induced ulcerative colitis.5
1.Vanhoof, R., Coignau, H., Stas, G., et al.Evaluation of the in vitro activity of nifuroxazide on enteropathogenic microorganisms: Determination of bacteriostatic and bactericidal concentrations and disk susceptibilityActa Clin. Belg.36(3)126-129(1981) 2.Yang, L., Rybtke, M.T., Jakobsen, T.H., et al.Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitorsAntimicrob. Agents Chemother.53(6)2432-2443(2009) 3.Nelson, E.A., Walker, S.R., Kepich, A., et al.Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Blood112(13)5095-5102(2008) 4.Yang, F., Hu, M., Lei, Q., et al.Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer modelCell Death Dis.6(3)e1701(2015) 5.El-Far, Y.M., Elsherbiny, N.M., El-Shafey, M., et al.The interplay of the inhibitory effect of nifuroxazide on NF-κB/STAT3 signaling attenuates acetic acid-induced ulcerative colitis in ratsEnviron. Toxicol. Pharmacol.79103433(2020)
| Cas No. | 1188487-83-3 | SDF | |
| Canonical SMILES | O=C(C1=C([2H])C([2H])=C(C([2H])=C1[2H])O)NN=CC2=CC=C([N+]([O-])=O)O2 | ||
| Formula | C12H5D4N3O5 | M.Wt | 279.2 |
| 溶解度 | DMF: soluble,DMSO: soluble | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5817 mL | 17.9083 mL | 35.8166 mL |
| 5 mM | 716.3 μL | 3.5817 mL | 7.1633 mL |
| 10 mM | 358.2 μL | 1.7908 mL | 3.5817 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)